|
FY2026
12 months to Feb 28, 2026
|
FY2025
12 months to Feb 28, 2025
|
FY2024
12 months to Feb 29, 2024
|
FY2023
12 months to Feb 28, 2023
|
FY2022
12 months to Feb 28, 2022
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Revenues | |||||
| Technology Licensing | |||||
| Product | |||||
| Service | |||||
| Total revenues | |||||
| Cost of Services | |||||
| Cost of Services | |||||
| Expenses: | |||||
| Research and development (Note 17) | |||||
| General and administrative (Note 18) | |||||
| Impairment of equipment (Note 6) | |||||
| Impairment of machinery & equipment (Note 6) | |||||
| Depreciation and amortization (Notes 6 and 7) | |||||
| Total expenses | |||||
| Gain on disposition of assets (Note 6) | |||||
| Contingency loss for legal settlement | |||||
| Interest and other financial expenses | |||||
| Loss on equity accounted investment (Note 11) | |||||
| Interest and other financial expenses (income) (Note 22) | |||||
| Interest income | |||||
| Foreign exchange gain | |||||
| Total other loss (income) | |||||
| Other loss: | |||||
| Loss on equity method investments (Note 11) | |||||
| Interest and Debt Expense | |||||
| Interest income | |||||
| Foreign exchange gain | |||||
| Total other loss | |||||
| Net loss | |||||
| Foreign currency translation adjustment | |||||
| Other comprehensive loss | |||||
| Foreign currency translation adjustment | |||||
| Comprehensive loss | |||||
| Net loss per share | |||||
| Basic and diluted | |||||
| Basic and diluted | |||||
| Basic and diluted (in dollars per share) | |||||
| Weighted average common shares outstanding | |||||
| Basic and diluted (in shares) | |||||
Loading...